KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2025)

Historic EBITDA for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' EBITDA fell 7967.28% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 8858.31%. This contributed to the annual value of -$479.0 million for FY2024, which is 3683.48% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported EBITDA of -$172.2 million as of Q3 2025, which was down 7967.28% from -$176.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year EBITDA high stood at -$30.5 million for Q1 2021, and its period low was -$191.4 million during Q1 2025.
  • Its 5-year average for EBITDA is -$93.2 million, with a median of -$76.7 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' EBITDA crashed by 15393.85% in 2021 and then soared by 612.38% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' EBITDA stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then plummeted by 85.76% to -$183.8 million in 2024, then rose by 6.29% to -$172.2 million in 2025.
  • Its EBITDA was -$172.2 million in Q3 2025, compared to -$176.2 million in Q2 2025 and -$191.4 million in Q1 2025.